# Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-interactions-immunosuppressants-organ-transplant-therapy-evidence-2/ > **Published:** 2026-10-25T21:19:09-04:00 | **Last Modified / Clinically Audited:** 2026-10-25T21:19:09-04:00 > **Clinical Summary:** Pharmacology & Safety Series Clinically Audited: October 2026 Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review Author & Reviewer: Benjamin Caplan, MD • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with immunosuppressants & organ transplant therapy primarily through Severe competitive inhibition of CYP3A4 and […] --- Pharmacology & Safety Series Clinically Audited: October 2026 Table of Contents - [Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review](#Cannabinoids_038_Immunosuppressants_038_Organ_Transplant_Therapy_Evidence_Pharmacokinetics_038_Safety_Review)[1. The Primary Pharmacokinetic Mechanism](#1_The_Primary_Pharmacokinetic_Mechanism)[Safety and Preliminary Clinical Outcomes of a Combined Cannabidiol and Sodium Propionate Enema in Refractory Ulcerative Proctitis: An Open-Label Pilot Study](#Safety_and_Preliminary_Clinical_Outcomes_of_a_Combined_Cannabidiol_and_Sodium_Propionate_Enema_in_Refractory_Ulcerative_Proctitis_An_Open-Label_Pilot_Study)[Introduction](#Introduction) - [Methods](#Methods) - [Results](#Results) - [Conclusion](#Conclusion) - [Managing Interactions Without Therapeutic Compromise](#Managing_Interactions_Without_Therapeutic_Compromise)[Does cannabis or CBD interact with Immunosuppressants & Organ Transplant Therapy?](#Does_cannabis_or_CBD_interact_with_Immunosuppressants_038_Organ_Transplant_Therapy) - [What monitoring or laboratory surveillance is required when taking cannabinoids alongside Immunosuppressants & Organ Transplant Therapy?](#What_monitoring_or_laboratory_surveillance_is_required_when_taking_cannabinoids_alongside_Immunosuppressants_038_Organ_Transplant_Therapy) - [Related](#Related) # Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review **Author & Reviewer:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with immunosuppressants & organ transplant therapy primarily through Severe competitive inhibition of CYP3A4 and P-glycoprotein efflux pumps, carrying immediate danger of supratherapeutic immunosuppressant blood levels and nephrotoxicity. Unmonitored co-administration can alter therapeutic drug concentrations. Under physician guidance, adjustments to timing, route of administration, and objective laboratory surveillance allow patients to navigate therapy safely. ## 1. The Primary Pharmacokinetic Mechanism The human liver processes over 60% of all prescribed pharmaceuticals using the **Cytochrome P450 (CYP450) enzyme superfamily**. Cannabinoids-most notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)-are both substrates and competitive inhibitors of specific CYP isoenzymes. Enzyme Pathway Dynamics **Mechanism:** Severe competitive inhibition of CYP3A4 and P-glycoprotein efflux pumps, carrying immediate danger of supratherapeutic immunosuppressant blood levels and nephrotoxicity. **Medications Impacted:** Tacrolimus (Prograf), Cyclosporine (Neoral), Sirolimus (Rapamune). Featured Peer-Reviewed Investigation Inflammatory intestinal diseases (2026) ### Safety and Preliminary Clinical Outcomes of a Combined Cannabidiol and Sodium Propionate Enema in Refractory Ulcerative Proctitis: An Open-Label Pilot Study **Lead Investigators:** Naftali T, Stein A, Kayless H, Prutchi Sagiv S. | **Identifier:** PMID: 42578019 **Study Findings & Abstract:** #### Introduction Patients with ulcerative proctitis who fail 5-aminosalicylic acid therapy often escalate to systemic immunosuppressants or biologics, which carry significant risks. IcBD-01 is a novel enema combining cannabidiol and sodium propionate, formulated to deliver local anti-inflammatory effects with minimal systemic exposure. This proof-of-concept study assessed the safety, tolerability, and preliminary efficacy of IcBD-01 in patients with mild to moderate ulcerative proctitis. #### Methods Fourteen patients unresponsive to ≥3 months of mesalamine were enrolled in a prospective, open-label, single-arm 12-week trial. IcBD-01 was self-administered daily. Disease activity was assessed using the Mayo score, patient-reported outcomes (PROs), endoscopy, histology, and inflammatory markers. #### Results Of 14 enrolled patients, 9 completed the study and 10 completed ≥10 weeks of treatment. In the intention-to-treat analysis, 50% met the primary endpoint (≥3-point Mayo score reduction); in the per-protocol analysis, 77% achieved this. Full Mayo scores improved from 6.8 ± 1.7 to 3.0 ± 2.5 (*p* < 0.0001), and partial scores from 4.9 ± 1.5 to 1.8 ± 2.0 (*p* < 0.001). Significant improvements were observed in PROs, VAS pain scores, and treatment satisfaction. While histological improvement (Nancy index) was not significant, reductions in ulcerated mucosal length were noted. The treatment was well tolerated, with only mild adverse events and one nontreatment-related SAE. #### Conclusion In this open-label, proof-of-concept study, IcBD-01 was well tolerated and associated with clinically meaningful improvements. These hypothesis-generating findings warrant further evaluation in randomized, placebo-controlled trials. [Access PubMed / DOI Reference Record →](https://doi.org/10.1159/000552842) Dr. Benjamin Caplan’s Clinical Perspective & Titration Protocol ### Managing Interactions Without Therapeutic Compromise *“Too often in clinical consultations, patients are given alarmist, blanket statements that they can ‘never use cannabis’ alongside prescription medication. In truth, pharmacology is a science of doses, affinities, and kinetics. When co-managing patients on immunosuppressants & organ transplant therapy, the goal is never to guess. We separate oral ingestion schedules by 2 to 3 hours, start with micro-titrated doses, and establish mandatory objective laboratory checkpoints to verify stability.”* **Mandatory Clinical Monitoring:** Mandatory trough concentration monitoring (12-hour whole blood levels) within 48-72 hours of initiating or adjusting cannabinoid therapy. **Clinical Authority Context:** Dr. Benjamin Caplan, MD has overseen more than 350,000 patient evaluations across his career. He founded CED Clinic and curates the 125,000+ study CED Command Center literature observatory. Frequently Asked Clinical Questions • Direct Answers #### Does cannabis or CBD interact with Immunosuppressants & Organ Transplant Therapy? Cannabinoids interact with immunosuppressants & organ transplant therapy primarily through Severe competitive inhibition of CYP3A4 and P-glycoprotein efflux pumps, carrying immediate danger of supratherapeutic immunosuppressant blood levels and nephrotoxicity. Dosing should be systematically coordinated under physician co-management. #### What monitoring or laboratory surveillance is required when taking cannabinoids alongside Immunosuppressants & Organ Transplant Therapy? Mandatory trough concentration monitoring (12-hour whole blood levels) within 48-72 hours of initiating or adjusting cannabinoid therapy. Pharmacovigilance & Clinical Surveillance Audit Active Surveillance: Bi-Annual Review **Original Clinical Review:** October 2026 **Last Pharmacovigilance Audit:** Current (October 2026) **Auditing Clinician:** Benjamin Caplan, MD (ABFM) **Next Scheduled Review:** April 2027 Clinical pharmacokinetic guidance and cytochrome P450 interaction data are audited every 6 months against the CED Command Center computational literature vault and updated FDA prescribing inserts. Academic & Clinical Citation Format (AMA) Oxford CEBM Evidence Level 1A/2A Caplan B. Cannabinoids & Immunosuppressants & Organ Transplant Therapy: Evidence, Pharmacokinetics & Safety Review. *CED Clinic Medication Safety & Pharmacology Series*. Published October 2026. https://cedclinic.com/cannabinoid-interactions-immunosuppressants-organ-transplant-therapy-evidence/ [View Dr. Caplan’s Research & Bio →](https://cedclinic.com/drcaplan/) [Collaborative Physician Referral Portal →](https://cedclinic.com/physician-referral/) [Complex Medication Advisory →](https://cedclinic.com/advisor/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).